108 related articles for article (PubMed ID: 29454888)
1. Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition.
Schnorr J; Fütterer S; Spicher K; Catarinolo M; Schlösser C; Enzmann H; Langguth P
Regul Toxicol Pharmacol; 2018 Apr; 94():293-298. PubMed ID: 29454888
[TBL] [Abstract][Full Text] [Related]
2. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
4. Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells.
Roth S; Langguth P; Spicher K; Enzmann H
Transl Res; 2008 Jan; 151(1):36-44. PubMed ID: 18061126
[TBL] [Abstract][Full Text] [Related]
5. Oxidative effect of several intravenous iron complexes in the rat.
Bailie GR; Schuler C; Leggett RE; Li H; Li HD; Patadia H; Levin R
Biometals; 2013 Jun; 26(3):473-8. PubMed ID: 23681275
[TBL] [Abstract][Full Text] [Related]
6. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
Pai AB
Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
8. Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver.
Spicher K; Brendler-Schwaab S; Schlösser C; Catarinolo M; Fütterer S; Langguth P; Enzmann H
Regul Toxicol Pharmacol; 2015 Oct; 73(1):65-72. PubMed ID: 26111606
[TBL] [Abstract][Full Text] [Related]
9. Ferrous iron content of intravenous iron formulations.
Gupta A; Pratt RD; Crumbliss AL
Biometals; 2016 Jun; 29(3):411-5. PubMed ID: 26956439
[TBL] [Abstract][Full Text] [Related]
10. [Importance of the different i.v. iron generations for everyday medical practice].
Biggar P; Hahn KM
MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies.
Borchard G; Flühmann B; Mühlebach S
Regul Toxicol Pharmacol; 2012 Nov; 64(2):324-8. PubMed ID: 22951348
[TBL] [Abstract][Full Text] [Related]
13. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations.
Span K; Pieters EHE; Brinks V; Hennink WE; Schellekens H
J Pharmacol Toxicol Methods; 2018; 91():7-17. PubMed ID: 29278742
[TBL] [Abstract][Full Text] [Related]
16. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
Di Francesco T; Philipp E; Borchard G
Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.
Pfenniger A; Schuller C; Christoph P; Surbek D
J Perinat Med; 2012 Apr; 40(4):397-402. PubMed ID: 22752771
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
[TBL] [Abstract][Full Text] [Related]
20. Parenteral iron therapy options.
Silverstein SB; Rodgers GM
Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
